Incannex delivers 2025 review, outlines 2026 outlook

Incannex (IXHL) Healthcare provides a 2025 corporate year-in-review and outlook for 2026, highlighting substantial clinical, regulatory and financial progress that positions the Company for continued execution. “The year 2025 was a defining one for Incannex,” stated Joel Latham, Incannex Healthcare Chief Executive Officer. “We delivered two independent, positive Phase 2 clinical readouts across distinct CNS programs, achieved FDA Fast Track designation for our lead OSA candidate, and materially strengthened our balance sheet. Importantly, we enter 2026 with more than $70 million in cash with runway extending well into 2027, allowing us to focus primarily on execution. With clinical validation, regulatory momentum and financial flexibility now in place, we are in a very exciting position as we advance our programs toward later-stage development and continue building long-term value for patients and shareholders.”